Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026Business Wire · 2 days ago
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers TranscriptSeeking Alpha · Oct 14, 2026
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase IIIMarketBeat · Oct 14, 2026
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple CancersBenzinga · Oct 14, 2026
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer DrugBarrons · Oct 14, 2026
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsBusiness Wire · Oct 14, 2026Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.43 | -$0.35 | Beat |
| May 7, 2026 | -$0.46 | -$0.37 | Beat |
| Mar 4, 2026 | -$0.49 | -$0.39 | Beat |
| Nov 4, 2025 | -$0.51 | -$1.35 | Miss |
| Aug 7, 2025 | -$0.85 | -$0.39 | Beat |
| May 13, 2025 | -$0.72 | -$0.96 | Miss |